Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Braze, Inc.BRZE · Entity 4102 | 10% owner | February 08, 2022 | February 09, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Braze, Inc.
Report date February 08, 2022 · Filed February 09, 2022
Jointly reported with InterWest Management Partners X, LLC, INTERWEST PARTNERS X LP, Kliman Gilbert H, NASR KHALED
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | IndirectBy: InterWest Partners X, LP | 3,394,219 |
Reported balance
After 2022-02-08 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2022-02-08 · Conversion · Acquired 3,394,219 · Balance 3,394,219 F1: Each share of Class B Common Stock, par value $0.001 per share (the "Class B Common Stock"), converted into one share of Class A Common Stock, par value $0.001 per share (the "Class A Common Stock"), at the option of the holder. F2: The reported securities are owned directly by InterWest Partners X, L.P. ("IW X"). The general partner of IW X is InterWest Management Partners X, LLC ("IMP X") and may be deemed to beneficially own the shares held by IW X. Gilbert H. Kliman is the managing director of IMP X and Keval Desai and Khaled A. Nasr are venture members of IMP X. The managing director and venture members of IMP X share voting and investment control with respect to the securities held by IW X. Each of IMP X, Mr. Kliman, Mr. Desai and Mr. Nasr disclaims beneficial ownership of these shares except to the extent of its or his respective pecuniary interest therein. |
| Class B Common StockSEC Table II · derivative / convertible security | IndirectBy: InterWest Partners X, LP | 0 |
Reported balance
After 2022-02-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-02-08 · Conversion · Disposed 3,394,219 · Balance 0 F1: Each share of Class B Common Stock, par value $0.001 per share (the "Class B Common Stock"), converted into one share of Class A Common Stock, par value $0.001 per share (the "Class A Common Stock"), at the option of the holder. F3: Each share of Class B Common Stock is convertible into one share of Class A Common Stock (A) at any time at the option of the Reporting Person or (B) automatically upon the occurrence of the following: (1) the transfer of such share of Class B Common Stock, except for certain transfers whereby the Reporting Person continues to hold sole voting and dispositive power with respect to each such share, (2) the death of a Class B common stockholder who is a natural person, (3) the last trading day of the fiscal quarter immediately following the fifth anniversary of the Issuer's initial public offering, (4) the date specified by affirmative vote of the holders of a majority of the outstanding shares of Class B common stock and (5) the last trading day of the fiscal quarter during which the then outstanding shares of Class B Common Stock first represent less than 10% of the aggregate number of shares of the then outstanding Class A Common Stock and Class B Common Stock. F2: The reported securities are owned directly by InterWest Partners X, L.P. ("IW X"). The general partner of IW X is InterWest Management Partners X, LLC ("IMP X") and may be deemed to beneficially own the shares held by IW X. Gilbert H. Kliman is the managing director of IMP X and Keval Desai and Khaled A. Nasr are venture members of IMP X. The managing director and venture members of IMP X share voting and investment control with respect to the securities held by IW X. Each of IMP X, Mr. Kliman, Mr. Desai and Mr. Nasr disclaims beneficial ownership of these shares except to the extent of its or his respective pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Class B Common Stock, par value $0.001 per share (the "Class B Common Stock"), converted into one share of Class A Common Stock, par value $0.001 per share (the "Class A Common Stock"), at the option of the holder.
F2: The reported securities are owned directly by InterWest Partners X, L.P. ("IW X"). The general partner of IW X is InterWest Management Partners X, LLC ("IMP X") and may be deemed to beneficially own the shares held by IW X. Gilbert H. Kliman is the managing director of IMP X and Keval Desai and Khaled A. Nasr are venture members of IMP X. The managing director and venture members of IMP X share voting and investment control with respect to the securities held by IW X. Each of IMP X, Mr. Kliman, Mr. Desai and Mr. Nasr disclaims beneficial ownership of these shares except to the extent of its or his respective pecuniary interest therein.
F3: Each share of Class B Common Stock is convertible into one share of Class A Common Stock (A) at any time at the option of the Reporting Person or (B) automatically upon the occurrence of the following: (1) the transfer of such share of Class B Common Stock, except for certain transfers whereby the Reporting Person continues to hold sole voting and dispositive power with respect to each such share, (2) the death of a Class B common stockholder who is a natural person, (3) the last trading day of the fiscal quarter immediately following the fifth anniversary of the Issuer's initial public offering, (4) the date specified by affirmative vote of the holders of a majority of the outstanding shares of Class B common stock and (5) the last trading day of the fiscal quarter during which the then outstanding shares of Class B Common Stock first represent less than 10% of the aggregate number of shares of the then outstanding Class A Common Stock and Class B Common Stock.
Past disclosures · reporting ended (5)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AVEDRO INC
Report date November 21, 2019 · Filed November 25, 2019
Jointly reported with INTERWEST PARTNERS X LP, InterWest Management Partners X, LLC, ORONSKY ARNOLD L, NASR KHALED, Kliman Gilbert H
Section 16 reporting ended · disclosed 2019-11-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-11-21 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2019-11-21 · Other · Disposed 2,742,239 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated as of August 7, 2019, by and among Avedro, Inc. (the "Issuer"), Glaukos Corporation ("Parent") and Atlantic Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), on November 21, 2019, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer continuing as the surviving corporation. Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of common stock of the Issuer ("Issuer Common Stock") that was issued and outstanding immediately prior to the Effective Time was automatically cancelled and converted into the right to receive 0.365 of a share of Parent's common stock ("Parent Common Stock"). The closing price of shares of the Parent Common Stock on November 21, 2019 was $63.07 per share. F2: The securities are directly held by InterWest Partners X, LP ("IW10"). InterWest Management Partners X, LLC ("IMP10"), as the general partner of IW10, may be deemed to beneficially own the shares held by IW10. Arnold L. Oronsky and Gilbert H. Kliman are Managing Directors of IMP10, and Khaled A. Nasr and Keal Desai are Venture Members of IMP10. Each of the foregoing persons may be deemed to beneficially own the shares held by IW10, and each foregoing person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2019-11-21 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2019-11-21 · Other · Disposed 3,005 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated as of August 7, 2019, by and among Avedro, Inc. (the "Issuer"), Glaukos Corporation ("Parent") and Atlantic Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), on November 21, 2019, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer continuing as the surviving corporation. Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of common stock of the Issuer ("Issuer Common Stock") that was issued and outstanding immediately prior to the Effective Time was automatically cancelled and converted into the right to receive 0.365 of a share of Parent's common stock ("Parent Common Stock"). The closing price of shares of the Parent Common Stock on November 21, 2019 was $63.07 per share. F3: The securities are directly held by InterWest Venture Management Company ("IVMC"). Gilbert H. Kliman transferred these shares to IVMC for no consideration pursuant to a contractual agreement between Kliman and IW10. Arnold L. Oronsky and Gilbert H. Kliman are owners, directors and officers of IVMC and as such may be deemed to beneficially own the shares held by IVMC. Each of Arnold L. Oronsky and Gilbert H. Kliman disclaim beneficial ownership of such shares except to the extend of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated as of August 7, 2019, by and among Avedro, Inc. (the "Issuer"), Glaukos Corporation ("Parent") and Atlantic Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), on November 21, 2019, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer continuing as the surviving corporation. Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of common stock of the Issuer ("Issuer Common Stock") that was issued and outstanding immediately prior to the Effective Time was automatically cancelled and converted into the right to receive 0.365 of a share of Parent's common stock ("Parent Common Stock"). The closing price of shares of the Parent Common Stock on November 21, 2019 was $63.07 per share.
F2: The securities are directly held by InterWest Partners X, LP ("IW10"). InterWest Management Partners X, LLC ("IMP10"), as the general partner of IW10, may be deemed to beneficially own the shares held by IW10. Arnold L. Oronsky and Gilbert H. Kliman are Managing Directors of IMP10, and Khaled A. Nasr and Keal Desai are Venture Members of IMP10. Each of the foregoing persons may be deemed to beneficially own the shares held by IW10, and each foregoing person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
F3: The securities are directly held by InterWest Venture Management Company ("IVMC"). Gilbert H. Kliman transferred these shares to IVMC for no consideration pursuant to a contractual agreement between Kliman and IW10. Arnold L. Oronsky and Gilbert H. Kliman are owners, directors and officers of IVMC and as such may be deemed to beneficially own the shares held by IVMC. Each of Arnold L. Oronsky and Gilbert H. Kliman disclaim beneficial ownership of such shares except to the extend of his pecuniary interest therein.
Doximity, Inc.
Report date December 02, 2021 · Filed December 06, 2021
Jointly reported with INTERWEST PARTNERS X LP, InterWest Management Partners X, LLC, NASR KHALED
Section 16 reporting ended · disclosed 2021-12-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 4,300,000 |
Reported balance
After 2021-12-02 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-12-02 · Conversion · Acquired 4,300,000 · Balance 4,300,000 F1: Each share of Class B Common Stock, par value $0.001 per share (the "Class B Common Stock"), converted into one share of Class A Common Stock, par value $0.001 per share (the "Class A Common Stock"), at the option of the holder. F4: These shares are directly held by IW10. IMP10 is the general partner of IW10. Gilbert H. Kliman is the Managing Director of IMP10. Keval Desai and Khaled Nasr are Venture Members of IMP10. Each of IMP10, Gilbert H. Kliman, Keval Desai and Khaled Nasr may be deemed to beneficially own the shares held by IW10, and each of IMP10, Gilbert H. Kliman, Keval Desai and Khaled Nasr disclaims beneficial ownership of only the shares held by IW10, except to the extent of its or his pecuniary interest therein. |
| Class A Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-12-02 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2021-12-02 · Other · Disposed 4,300,000 · Balance 0 F2: Represents pro rata in-kind distribution by InterWest Partners X, LP ("IW10") without consideration to its limited and general partners in accordance with the terms of the InterWest Partners X, LP Limited Partnership Agreement. Includes 1,101,094 shares distributed to InterWest Management Partners X, LLC ("IMP10") its general partner. |
| Class A Common StockSEC Table I · non-derivative | IndirectBy: InterWest Management Partners X, LLC | 0 |
Last balance in matching sequence
After 2021-12-02 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 3 · 2021-12-02 · Other · Acquired 1,101,094 · Balance 1,101,094 F2: Represents pro rata in-kind distribution by InterWest Partners X, LP ("IW10") without consideration to its limited and general partners in accordance with the terms of the InterWest Partners X, LP Limited Partnership Agreement. Includes 1,101,094 shares distributed to InterWest Management Partners X, LLC ("IMP10") its general partner. F4: These shares are directly held by IW10. IMP10 is the general partner of IW10. Gilbert H. Kliman is the Managing Director of IMP10. Keval Desai and Khaled Nasr are Venture Members of IMP10. Each of IMP10, Gilbert H. Kliman, Keval Desai and Khaled Nasr may be deemed to beneficially own the shares held by IW10, and each of IMP10, Gilbert H. Kliman, Keval Desai and Khaled Nasr disclaims beneficial ownership of only the shares held by IW10, except to the extent of its or his pecuniary interest therein. Row 4 · 2021-12-02 · Other · Disposed 1,101,094 · Balance 0 F3: Represents pro rata in-kind distribution by IMP10 without consideration to its members in accordance with the terms of the InterWest Management Partners X, LLC Operating Agreement. Includes 41,070 shares distributed to Khaled A. Nasr ("Nasr"), 27,527 shares distributed to Keval Desai ("Desai") and 249,778 shares distributed to Gilbert H. Kliman ("Kliman"), as reported on Kliman's separate Form 4 in his own name. F4: These shares are directly held by IW10. IMP10 is the general partner of IW10. Gilbert H. Kliman is the Managing Director of IMP10. Keval Desai and Khaled Nasr are Venture Members of IMP10. Each of IMP10, Gilbert H. Kliman, Keval Desai and Khaled Nasr may be deemed to beneficially own the shares held by IW10, and each of IMP10, Gilbert H. Kliman, Keval Desai and Khaled Nasr disclaims beneficial ownership of only the shares held by IW10, except to the extent of its or his pecuniary interest therein. |
| Class A Common StockSEC Table I · non-derivative | IndirectBy: Khaled A. Nasr | 81,696 |
Reported balance
After 2021-12-02 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2021-12-02 · Other · Acquired 41,070 · Balance 81,696 F3: Represents pro rata in-kind distribution by IMP10 without consideration to its members in accordance with the terms of the InterWest Management Partners X, LLC Operating Agreement. Includes 41,070 shares distributed to Khaled A. Nasr ("Nasr"), 27,527 shares distributed to Keval Desai ("Desai") and 249,778 shares distributed to Gilbert H. Kliman ("Kliman"), as reported on Kliman's separate Form 4 in his own name. F4: These shares are directly held by IW10. IMP10 is the general partner of IW10. Gilbert H. Kliman is the Managing Director of IMP10. Keval Desai and Khaled Nasr are Venture Members of IMP10. Each of IMP10, Gilbert H. Kliman, Keval Desai and Khaled Nasr may be deemed to beneficially own the shares held by IW10, and each of IMP10, Gilbert H. Kliman, Keval Desai and Khaled Nasr disclaims beneficial ownership of only the shares held by IW10, except to the extent of its or his pecuniary interest therein. |
| Class A Common StockSEC Table I · non-derivative | IndirectBy: Keval Desai | 54,756 |
Reported balance
After 2021-12-02 transaction · row 6
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 6 · 2021-12-02 · Other · Acquired 27,527 · Balance 54,756 F3: Represents pro rata in-kind distribution by IMP10 without consideration to its members in accordance with the terms of the InterWest Management Partners X, LLC Operating Agreement. Includes 41,070 shares distributed to Khaled A. Nasr ("Nasr"), 27,527 shares distributed to Keval Desai ("Desai") and 249,778 shares distributed to Gilbert H. Kliman ("Kliman"), as reported on Kliman's separate Form 4 in his own name. F4: These shares are directly held by IW10. IMP10 is the general partner of IW10. Gilbert H. Kliman is the Managing Director of IMP10. Keval Desai and Khaled Nasr are Venture Members of IMP10. Each of IMP10, Gilbert H. Kliman, Keval Desai and Khaled Nasr may be deemed to beneficially own the shares held by IW10, and each of IMP10, Gilbert H. Kliman, Keval Desai and Khaled Nasr disclaims beneficial ownership of only the shares held by IW10, except to the extent of its or his pecuniary interest therein. |
| Class B Common StockSEC Table II · derivative / convertible security | Direct | 8,556,998 |
Reported balance
After 2021-12-02 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-12-02 · Conversion · Disposed 4,300,000 · Balance 8,556,998 F5: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at any time at the option of the holder. Each share of Class B Common Stock held by the Reporting Person will automatically convert into one share of Class A Common Stock, upon the following: (1) the sale or transfer of such share of Class B Common Stock, except for certain permitted transfers described in the Issuer's amended and restated certificate of incorporation; (2) the death or incapacity of the Reporting Person; and (3) on the final conversion date, defined as the earlier of (a) the tenth anniversary of the effectiveness of the registration statement in connection with the IPO; or (b) the date specified by a vote of the holders of at least 66 2/3% of the outstanding shares of Class B Common Stock, voting as a single class. F1: Each share of Class B Common Stock, par value $0.001 per share (the "Class B Common Stock"), converted into one share of Class A Common Stock, par value $0.001 per share (the "Class A Common Stock"), at the option of the holder. F4: These shares are directly held by IW10. IMP10 is the general partner of IW10. Gilbert H. Kliman is the Managing Director of IMP10. Keval Desai and Khaled Nasr are Venture Members of IMP10. Each of IMP10, Gilbert H. Kliman, Keval Desai and Khaled Nasr may be deemed to beneficially own the shares held by IW10, and each of IMP10, Gilbert H. Kliman, Keval Desai and Khaled Nasr disclaims beneficial ownership of only the shares held by IW10, except to the extent of its or his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Class B Common Stock, par value $0.001 per share (the "Class B Common Stock"), converted into one share of Class A Common Stock, par value $0.001 per share (the "Class A Common Stock"), at the option of the holder.
F2: Represents pro rata in-kind distribution by InterWest Partners X, LP ("IW10") without consideration to its limited and general partners in accordance with the terms of the InterWest Partners X, LP Limited Partnership Agreement. Includes 1,101,094 shares distributed to InterWest Management Partners X, LLC ("IMP10") its general partner.
F3: Represents pro rata in-kind distribution by IMP10 without consideration to its members in accordance with the terms of the InterWest Management Partners X, LLC Operating Agreement. Includes 41,070 shares distributed to Khaled A. Nasr ("Nasr"), 27,527 shares distributed to Keval Desai ("Desai") and 249,778 shares distributed to Gilbert H. Kliman ("Kliman"), as reported on Kliman's separate Form 4 in his own name.
F4: These shares are directly held by IW10. IMP10 is the general partner of IW10. Gilbert H. Kliman is the Managing Director of IMP10. Keval Desai and Khaled Nasr are Venture Members of IMP10. Each of IMP10, Gilbert H. Kliman, Keval Desai and Khaled Nasr may be deemed to beneficially own the shares held by IW10, and each of IMP10, Gilbert H. Kliman, Keval Desai and Khaled Nasr disclaims beneficial ownership of only the shares held by IW10, except to the extent of its or his pecuniary interest therein.
F5: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at any time at the option of the holder. Each share of Class B Common Stock held by the Reporting Person will automatically convert into one share of Class A Common Stock, upon the following: (1) the sale or transfer of such share of Class B Common Stock, except for certain permitted transfers described in the Issuer's amended and restated certificate of incorporation; (2) the death or incapacity of the Reporting Person; and (3) on the final conversion date, defined as the earlier of (a) the tenth anniversary of the effectiveness of the registration statement in connection with the IPO; or (b) the date specified by a vote of the holders of at least 66 2/3% of the outstanding shares of Class B Common Stock, voting as a single class.
Eiger BioPharmaceuticals, Inc.
Report date October 18, 2018 · Filed October 22, 2018
Jointly reported with INTERWEST PARTNERS X LP, InterWest Management Partners X, LLC, Kliman Gilbert H, ORONSKY ARNOLD L, NASR KHALED
Section 16 reporting ended · disclosed 2018-10-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,362,327 |
Last balance in matching sequence
After 2018-10-18 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2018-10-18 · Sale · Disposed 210,800 · Balance 1,388,792 F1: Price reflected is the weighted-average sale price for shares sold. The range of sale prices for the transactions reported was $12.00 to $12.30 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F3: These securities are held of record by InterWest Partners X, L.P. ("IW10"). InterWest Management Partners X, LLC ("IMP10") is the general partner of IW10 and has sole voting and investment control over the shares owned by IW10. Gilbert H. Kliman, and Arnold L. Oronsky are Managing Directors of IMP10 and, Keval Desai and Khaled A. Nasr, are Venture Members of IMP10. All Reporting Persons disclaim beneficial ownership of shares of Eiger BioPharmaceuticals, Inc. stock held by IW10, except to the extent of their respective pecuniary interest therein. The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1944, or otherwise, any of the Reporting Persons are the beneficial owner of all of the equity securities covered by this statement. Row 2 · 2018-10-18 · Sale · Disposed 26,465 · Balance 1,362,327 F2: Price reflected is the weighted-average sale price for shares sold. The range of sale prices for the transactions reported was $12.00 to $12.03 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F3: These securities are held of record by InterWest Partners X, L.P. ("IW10"). InterWest Management Partners X, LLC ("IMP10") is the general partner of IW10 and has sole voting and investment control over the shares owned by IW10. Gilbert H. Kliman, and Arnold L. Oronsky are Managing Directors of IMP10 and, Keval Desai and Khaled A. Nasr, are Venture Members of IMP10. All Reporting Persons disclaim beneficial ownership of shares of Eiger BioPharmaceuticals, Inc. stock held by IW10, except to the extent of their respective pecuniary interest therein. The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1944, or otherwise, any of the Reporting Persons are the beneficial owner of all of the equity securities covered by this statement. |
Filing footnotes · ownership attribution and instrument terms
F1: Price reflected is the weighted-average sale price for shares sold. The range of sale prices for the transactions reported was $12.00 to $12.30 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F2: Price reflected is the weighted-average sale price for shares sold. The range of sale prices for the transactions reported was $12.00 to $12.03 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F3: These securities are held of record by InterWest Partners X, L.P. ("IW10"). InterWest Management Partners X, LLC ("IMP10") is the general partner of IW10 and has sole voting and investment control over the shares owned by IW10. Gilbert H. Kliman, and Arnold L. Oronsky are Managing Directors of IMP10 and, Keval Desai and Khaled A. Nasr, are Venture Members of IMP10. All Reporting Persons disclaim beneficial ownership of shares of Eiger BioPharmaceuticals, Inc. stock held by IW10, except to the extent of their respective pecuniary interest therein. The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1944, or otherwise, any of the Reporting Persons are the beneficial owner of all of the equity securities covered by this statement.
PMV Pharmaceuticals, Inc.
Report date July 13, 2021 · Filed July 14, 2021
Jointly reported with INTERWEST PARTNERS X LP, InterWest Management Partners X, LLC, NASR KHALED, Kliman Gilbert H
Section 16 reporting ended · disclosed 2021-07-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,469,911 |
Reported balance
After 2021-07-13 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-07-13 · Other · Disposed 500,000 · Balance 4,469,911 F1: Represents pro rata in-kind distribution by InterWest Partners X, LP ("IW10") without consideration to its limited and general partners in accordance with the terms of the InterWest Partners X, LP Limited Partnership Agreement. Includes 97,632 shares distributed to InterWest Management Partners X, LLC ("IMP10") its general partner. |
| Common StockSEC Table I · non-derivative | IndirectBy: InterWest Management Partners X, LLC | 0 |
Last balance in matching sequence
After 2021-07-13 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 2 · 2021-07-13 · Other · Acquired 97,632 · Balance 97,632 F1: Represents pro rata in-kind distribution by InterWest Partners X, LP ("IW10") without consideration to its limited and general partners in accordance with the terms of the InterWest Partners X, LP Limited Partnership Agreement. Includes 97,632 shares distributed to InterWest Management Partners X, LLC ("IMP10") its general partner. F3: The shares are held directly by IW10. The general partner of IW10 is IMP10. Kliman is a Managing Director of IMP10 and Nasr and Desai are Venture Members of IMP10. Each of Nasr, Desai and Kliman share voting and investment control over the shares owned by IW10, and may be deemed to beneficially own the shares held by IW10. Each of Nasr, Desai and Kliman disclaims beneficial ownership of such shares except to the extent of his pecuniaryinterest theriein. Row 3 · 2021-07-13 · Other · Disposed 97,632 · Balance 0 F2: Represents pro rata in-kind distribution by IMP10 without consideration to its members in accordance with the terms of the InterWest Management Partners X, LLC Operating Agreement. Includes 3,642 shares distributed to Khaled A. Nasr ("Nasr"), 2,441 shares distributed to Keval Desai ("Desai") and 22,148 shares distributed to Gilbert H. Kliman ("Kliman"). F3: The shares are held directly by IW10. The general partner of IW10 is IMP10. Kliman is a Managing Director of IMP10 and Nasr and Desai are Venture Members of IMP10. Each of Nasr, Desai and Kliman share voting and investment control over the shares owned by IW10, and may be deemed to beneficially own the shares held by IW10. Each of Nasr, Desai and Kliman disclaims beneficial ownership of such shares except to the extent of his pecuniaryinterest theriein. |
| Common StockSEC Table I · non-derivative | IndirectBy: Khaled A. Nasr | 4,201 |
Reported balance
After 2021-07-13 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2021-07-13 · Other · Acquired 3,642 · Balance 4,201 F2: Represents pro rata in-kind distribution by IMP10 without consideration to its members in accordance with the terms of the InterWest Management Partners X, LLC Operating Agreement. Includes 3,642 shares distributed to Khaled A. Nasr ("Nasr"), 2,441 shares distributed to Keval Desai ("Desai") and 22,148 shares distributed to Gilbert H. Kliman ("Kliman"). F3: The shares are held directly by IW10. The general partner of IW10 is IMP10. Kliman is a Managing Director of IMP10 and Nasr and Desai are Venture Members of IMP10. Each of Nasr, Desai and Kliman share voting and investment control over the shares owned by IW10, and may be deemed to beneficially own the shares held by IW10. Each of Nasr, Desai and Kliman disclaims beneficial ownership of such shares except to the extent of his pecuniaryinterest theriein. |
| Common StockSEC Table I · non-derivative | IndirectBy: Keval Desai | 2,816 |
Reported balance
After 2021-07-13 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2021-07-13 · Other · Acquired 2,441 · Balance 2,816 F2: Represents pro rata in-kind distribution by IMP10 without consideration to its members in accordance with the terms of the InterWest Management Partners X, LLC Operating Agreement. Includes 3,642 shares distributed to Khaled A. Nasr ("Nasr"), 2,441 shares distributed to Keval Desai ("Desai") and 22,148 shares distributed to Gilbert H. Kliman ("Kliman"). F3: The shares are held directly by IW10. The general partner of IW10 is IMP10. Kliman is a Managing Director of IMP10 and Nasr and Desai are Venture Members of IMP10. Each of Nasr, Desai and Kliman share voting and investment control over the shares owned by IW10, and may be deemed to beneficially own the shares held by IW10. Each of Nasr, Desai and Kliman disclaims beneficial ownership of such shares except to the extent of his pecuniaryinterest theriein. |
| Common StockSEC Table I · non-derivative | IndirectBy Gilbert H. Kliman | 25,552 |
Reported balance
After 2021-07-13 transaction · row 6
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 6 · 2021-07-13 · Other · Acquired 22,148 · Balance 25,552 F2: Represents pro rata in-kind distribution by IMP10 without consideration to its members in accordance with the terms of the InterWest Management Partners X, LLC Operating Agreement. Includes 3,642 shares distributed to Khaled A. Nasr ("Nasr"), 2,441 shares distributed to Keval Desai ("Desai") and 22,148 shares distributed to Gilbert H. Kliman ("Kliman"). F3: The shares are held directly by IW10. The general partner of IW10 is IMP10. Kliman is a Managing Director of IMP10 and Nasr and Desai are Venture Members of IMP10. Each of Nasr, Desai and Kliman share voting and investment control over the shares owned by IW10, and may be deemed to beneficially own the shares held by IW10. Each of Nasr, Desai and Kliman disclaims beneficial ownership of such shares except to the extent of his pecuniaryinterest theriein. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents pro rata in-kind distribution by InterWest Partners X, LP ("IW10") without consideration to its limited and general partners in accordance with the terms of the InterWest Partners X, LP Limited Partnership Agreement. Includes 97,632 shares distributed to InterWest Management Partners X, LLC ("IMP10") its general partner.
F2: Represents pro rata in-kind distribution by IMP10 without consideration to its members in accordance with the terms of the InterWest Management Partners X, LLC Operating Agreement. Includes 3,642 shares distributed to Khaled A. Nasr ("Nasr"), 2,441 shares distributed to Keval Desai ("Desai") and 22,148 shares distributed to Gilbert H. Kliman ("Kliman").
F3: The shares are held directly by IW10. The general partner of IW10 is IMP10. Kliman is a Managing Director of IMP10 and Nasr and Desai are Venture Members of IMP10. Each of Nasr, Desai and Kliman share voting and investment control over the shares owned by IW10, and may be deemed to beneficially own the shares held by IW10. Each of Nasr, Desai and Kliman disclaims beneficial ownership of such shares except to the extent of his pecuniaryinterest theriein.
Vyome Holdings, Inc
Report date August 06, 2019 · Filed August 08, 2019
Jointly reported with INTERWEST PARTNERS X LP, InterWest Management Partners X, LLC, Kliman Gilbert H, ORONSKY ARNOLD L, NASR KHALED
Section 16 reporting ended · disclosed 2019-08-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 380,224 |
Reported balance
After 2019-08-06 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2019-08-06 · Purchase · Acquired 25,000 · Balance 380,224 F1: The reporting persons purchased these shares directly from the underwriter in the Issuer's registered offering of Common Stock with 75% warrant coverage at a price of $4.00 per unit. There was no additional consideration paid for the warrants. F2: These securities are held of record by InterWest Partners X, L.P. ("IW10"). InterWest Management Partners X, LLC ("IMP10") is the general partner of IW10 and has sole voting and investment control over the shares owned by IW10. Gilbert H. Kliman, and Arnold L. Oronsky are Managing Directors of IMP10 and, Keval Desai and Khaled A. Nasr, and are Venture Members of IMP10. Douglas Fisher, a Member of IMP10 is also a Director of the Issuer, and when required, files a separate Form 4 in his own name. All Reporting Persons disclaim beneficial ownership of shares of Obalon Therapeutics, Inc. stock held by IW10, except to the extent of their respective pecuniary interest therein. The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1944, or otherwise, any of the Reporting Persons are the beneficial owner of all of the equity securities covered by this statement. |
| Warrants (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.40 · Expires 2024-08-05 | Direct | 18,750 |
Reported balance
After 2019-08-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-08-06 · Purchase · Acquired 18,750 · Balance 18,750 F1: The reporting persons purchased these shares directly from the underwriter in the Issuer's registered offering of Common Stock with 75% warrant coverage at a price of $4.00 per unit. There was no additional consideration paid for the warrants. F2: These securities are held of record by InterWest Partners X, L.P. ("IW10"). InterWest Management Partners X, LLC ("IMP10") is the general partner of IW10 and has sole voting and investment control over the shares owned by IW10. Gilbert H. Kliman, and Arnold L. Oronsky are Managing Directors of IMP10 and, Keval Desai and Khaled A. Nasr, and are Venture Members of IMP10. Douglas Fisher, a Member of IMP10 is also a Director of the Issuer, and when required, files a separate Form 4 in his own name. All Reporting Persons disclaim beneficial ownership of shares of Obalon Therapeutics, Inc. stock held by IW10, except to the extent of their respective pecuniary interest therein. The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1944, or otherwise, any of the Reporting Persons are the beneficial owner of all of the equity securities covered by this statement. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting persons purchased these shares directly from the underwriter in the Issuer's registered offering of Common Stock with 75% warrant coverage at a price of $4.00 per unit. There was no additional consideration paid for the warrants.
F2: These securities are held of record by InterWest Partners X, L.P. ("IW10"). InterWest Management Partners X, LLC ("IMP10") is the general partner of IW10 and has sole voting and investment control over the shares owned by IW10. Gilbert H. Kliman, and Arnold L. Oronsky are Managing Directors of IMP10 and, Keval Desai and Khaled A. Nasr, and are Venture Members of IMP10. Douglas Fisher, a Member of IMP10 is also a Director of the Issuer, and when required, files a separate Form 4 in his own name. All Reporting Persons disclaim beneficial ownership of shares of Obalon Therapeutics, Inc. stock held by IW10, except to the extent of their respective pecuniary interest therein. The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1944, or otherwise, any of the Reporting Persons are the beneficial owner of all of the equity securities covered by this statement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 29, 2020 Filed Sep 29, 2020 16:35 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | ConversionSeries C Preferred Stock · Derivative | 265,203 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052335 · doc4.xml · derivative · entry 9 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Desai Keval · CIK 0001553019 · 10% owner Kliman Gilbert H · CIK 0001293171 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 265,203 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F2 · derivative.exercise_date: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F2 · derivative.expiration_date: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1 · ownership.direct: The securities are directly held by InterWest Partners X, LP ("IW10"). InterWest Management Partners X, LLC ("IMP10"), as the general partner of IW10, may be deemed to beneficially own the shares held by IW10. Arnold L. Oronsky and Gilbert H. Kliman are Managing Directors of IMP10, and Khaled A. Nasr and Keal Desai are Venture Members of IMP10. Each of the foregoing persons may be deemed to beneficially own the shares held by IW10, and each foregoing person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| September 29, 2020 Filed Sep 29, 2020 16:35 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | ConversionSeries B Preferred Stock · Derivative | 1,040,654 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052335 · doc4.xml · derivative · entry 8 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Desai Keval · CIK 0001553019 · 10% owner Kliman Gilbert H · CIK 0001293171 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,040,654 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F2 · derivative.exercise_date: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F2 · derivative.expiration_date: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1 · ownership.direct: The securities are directly held by InterWest Partners X, LP ("IW10"). InterWest Management Partners X, LLC ("IMP10"), as the general partner of IW10, may be deemed to beneficially own the shares held by IW10. Arnold L. Oronsky and Gilbert H. Kliman are Managing Directors of IMP10, and Khaled A. Nasr and Keal Desai are Venture Members of IMP10. Each of the foregoing persons may be deemed to beneficially own the shares held by IW10, and each foregoing person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| September 29, 2020 Filed Sep 29, 2020 16:35 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | ConversionSeries A Preferred Stock · Derivative | 3,488,398 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052335 · doc4.xml · derivative · entry 7 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Desai Keval · CIK 0001553019 · 10% owner Kliman Gilbert H · CIK 0001293171 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,488,398 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F2 · derivative.exercise_date: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F2 · derivative.expiration_date: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1 · ownership.direct: The securities are directly held by InterWest Partners X, LP ("IW10"). InterWest Management Partners X, LLC ("IMP10"), as the general partner of IW10, may be deemed to beneficially own the shares held by IW10. Arnold L. Oronsky and Gilbert H. Kliman are Managing Directors of IMP10, and Khaled A. Nasr and Keal Desai are Venture Members of IMP10. Each of the foregoing persons may be deemed to beneficially own the shares held by IW10, and each foregoing person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| September 29, 2020 Filed Sep 29, 2020 16:35 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | ConversionSeries Seed Preferred Stock · Derivative | 1,620,101 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052335 · doc4.xml · derivative · entry 6 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Desai Keval · CIK 0001553019 · 10% owner Kliman Gilbert H · CIK 0001293171 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,620,101 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F2 · derivative.exercise_date: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F2 · derivative.expiration_date: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1 · ownership.direct: The securities are directly held by InterWest Partners X, LP ("IW10"). InterWest Management Partners X, LLC ("IMP10"), as the general partner of IW10, may be deemed to beneficially own the shares held by IW10. Arnold L. Oronsky and Gilbert H. Kliman are Managing Directors of IMP10, and Khaled A. Nasr and Keal Desai are Venture Members of IMP10. Each of the foregoing persons may be deemed to beneficially own the shares held by IW10, and each foregoing person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| September 29, 2020 Filed Sep 29, 2020 16:35 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | ConversionCommon Stock | 265,203 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-052335 · doc4.xml · nonDerivative · entry 5 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Desai Keval · CIK 0001553019 · 10% owner Kliman Gilbert H · CIK 0001293171 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,469,356 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1 · ownership.direct: The securities are directly held by InterWest Partners X, LP ("IW10"). InterWest Management Partners X, LLC ("IMP10"), as the general partner of IW10, may be deemed to beneficially own the shares held by IW10. Arnold L. Oronsky and Gilbert H. Kliman are Managing Directors of IMP10, and Khaled A. Nasr and Keal Desai are Venture Members of IMP10. Each of the foregoing persons may be deemed to beneficially own the shares held by IW10, and each foregoing person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| September 29, 2020 Filed Sep 29, 2020 16:35 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | ConversionCommon Stock | 1,040,654 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-052335 · doc4.xml · nonDerivative · entry 4 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Desai Keval · CIK 0001553019 · 10% owner Kliman Gilbert H · CIK 0001293171 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,204,153 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1 · ownership.direct: The securities are directly held by InterWest Partners X, LP ("IW10"). InterWest Management Partners X, LLC ("IMP10"), as the general partner of IW10, may be deemed to beneficially own the shares held by IW10. Arnold L. Oronsky and Gilbert H. Kliman are Managing Directors of IMP10, and Khaled A. Nasr and Keal Desai are Venture Members of IMP10. Each of the foregoing persons may be deemed to beneficially own the shares held by IW10, and each foregoing person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| September 29, 2020 Filed Sep 29, 2020 16:35 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | ConversionCommon Stock | 3,488,398 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-052335 · doc4.xml · nonDerivative · entry 3 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Desai Keval · CIK 0001553019 · 10% owner Kliman Gilbert H · CIK 0001293171 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,163,499 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1 · ownership.direct: The securities are directly held by InterWest Partners X, LP ("IW10"). InterWest Management Partners X, LLC ("IMP10"), as the general partner of IW10, may be deemed to beneficially own the shares held by IW10. Arnold L. Oronsky and Gilbert H. Kliman are Managing Directors of IMP10, and Khaled A. Nasr and Keal Desai are Venture Members of IMP10. Each of the foregoing persons may be deemed to beneficially own the shares held by IW10, and each foregoing person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| September 29, 2020 Filed Sep 29, 2020 16:35 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | ConversionCommon Stock | 1,620,101 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-052335 · doc4.xml · nonDerivative · entry 2 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Desai Keval · CIK 0001553019 · 10% owner Kliman Gilbert H · CIK 0001293171 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,675,101 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1 · ownership.direct: The securities are directly held by InterWest Partners X, LP ("IW10"). InterWest Management Partners X, LLC ("IMP10"), as the general partner of IW10, may be deemed to beneficially own the shares held by IW10. Arnold L. Oronsky and Gilbert H. Kliman are Managing Directors of IMP10, and Khaled A. Nasr and Keal Desai are Venture Members of IMP10. Each of the foregoing persons may be deemed to beneficially own the shares held by IW10, and each foregoing person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| September 29, 2020 Filed Oct 2, 2020 18:41 UTC Amendment | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | ConversionSeries C Preferred Stock · Derivative | 265,203 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-053342 · doc4a.xml · derivative · entry 9 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Desai Keval · CIK 0001553019 · 10% owner Kliman Gilbert H · CIK 0001293171 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 265,203 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F2 · derivative.exercise_date: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F2 · derivative.expiration_date: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1 · ownership.direct: The securities are directly held by InterWest Partners X, LP ("IW10"). InterWest Management Partners X, LLC ("IMP10"), as the general partner of IW10, may be deemed to beneficially own the shares held by IW10. Arnold L. Oronsky and Gilbert H. Kliman are Managing Directors of IMP10, and Khaled A. Nasr and Keal Desai are Venture Members of IMP10. Each of the foregoing persons may be deemed to beneficially own the shares held by IW10, and each foregoing person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| September 29, 2020 Filed Oct 2, 2020 18:41 UTC Amendment | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | ConversionSeries B Preferred Stock · Derivative | 1,040,654 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-053342 · doc4a.xml · derivative · entry 8 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Desai Keval · CIK 0001553019 · 10% owner Kliman Gilbert H · CIK 0001293171 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,040,654 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F2 · derivative.exercise_date: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F2 · derivative.expiration_date: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1 · ownership.direct: The securities are directly held by InterWest Partners X, LP ("IW10"). InterWest Management Partners X, LLC ("IMP10"), as the general partner of IW10, may be deemed to beneficially own the shares held by IW10. Arnold L. Oronsky and Gilbert H. Kliman are Managing Directors of IMP10, and Khaled A. Nasr and Keal Desai are Venture Members of IMP10. Each of the foregoing persons may be deemed to beneficially own the shares held by IW10, and each foregoing person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| September 29, 2020 Filed Oct 2, 2020 18:41 UTC Amendment | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | ConversionSeries A Preferred Stock · Derivative | 3,488,398 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-053342 · doc4a.xml · derivative · entry 7 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Desai Keval · CIK 0001553019 · 10% owner Kliman Gilbert H · CIK 0001293171 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,488,398 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F2 · derivative.exercise_date: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F2 · derivative.expiration_date: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1 · ownership.direct: The securities are directly held by InterWest Partners X, LP ("IW10"). InterWest Management Partners X, LLC ("IMP10"), as the general partner of IW10, may be deemed to beneficially own the shares held by IW10. Arnold L. Oronsky and Gilbert H. Kliman are Managing Directors of IMP10, and Khaled A. Nasr and Keal Desai are Venture Members of IMP10. Each of the foregoing persons may be deemed to beneficially own the shares held by IW10, and each foregoing person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| September 29, 2020 Filed Oct 2, 2020 18:41 UTC Amendment | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | ConversionSeries Seed Preferred Stock · Derivative | 1,620,101 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-053342 · doc4a.xml · derivative · entry 6 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Desai Keval · CIK 0001553019 · 10% owner Kliman Gilbert H · CIK 0001293171 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,620,101 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F2 · derivative.exercise_date: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F2 · derivative.expiration_date: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1 · ownership.direct: The securities are directly held by InterWest Partners X, LP ("IW10"). InterWest Management Partners X, LLC ("IMP10"), as the general partner of IW10, may be deemed to beneficially own the shares held by IW10. Arnold L. Oronsky and Gilbert H. Kliman are Managing Directors of IMP10, and Khaled A. Nasr and Keal Desai are Venture Members of IMP10. Each of the foregoing persons may be deemed to beneficially own the shares held by IW10, and each foregoing person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| September 29, 2020 Filed Oct 2, 2020 18:41 UTC Amendment | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | ConversionCommon Stock | 265,203 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-053342 · doc4a.xml · nonDerivative · entry 5 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Desai Keval · CIK 0001553019 · 10% owner Kliman Gilbert H · CIK 0001293171 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,469,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1 · ownership.direct: The securities are directly held by InterWest Partners X, LP ("IW10"). InterWest Management Partners X, LLC ("IMP10"), as the general partner of IW10, may be deemed to beneficially own the shares held by IW10. Arnold L. Oronsky and Gilbert H. Kliman are Managing Directors of IMP10, and Khaled A. Nasr and Keal Desai are Venture Members of IMP10. Each of the foregoing persons may be deemed to beneficially own the shares held by IW10, and each foregoing person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| September 29, 2020 Filed Oct 2, 2020 18:41 UTC Amendment | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | ConversionCommon Stock | 1,040,654 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-053342 · doc4a.xml · nonDerivative · entry 4 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Desai Keval · CIK 0001553019 · 10% owner Kliman Gilbert H · CIK 0001293171 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,204,708 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1 · ownership.direct: The securities are directly held by InterWest Partners X, LP ("IW10"). InterWest Management Partners X, LLC ("IMP10"), as the general partner of IW10, may be deemed to beneficially own the shares held by IW10. Arnold L. Oronsky and Gilbert H. Kliman are Managing Directors of IMP10, and Khaled A. Nasr and Keal Desai are Venture Members of IMP10. Each of the foregoing persons may be deemed to beneficially own the shares held by IW10, and each foregoing person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| September 29, 2020 Filed Oct 2, 2020 18:41 UTC Amendment | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | ConversionCommon Stock | 3,488,398 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-053342 · doc4a.xml · nonDerivative · entry 3 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Desai Keval · CIK 0001553019 · 10% owner Kliman Gilbert H · CIK 0001293171 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,164,054 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1 · ownership.direct: The securities are directly held by InterWest Partners X, LP ("IW10"). InterWest Management Partners X, LLC ("IMP10"), as the general partner of IW10, may be deemed to beneficially own the shares held by IW10. Arnold L. Oronsky and Gilbert H. Kliman are Managing Directors of IMP10, and Khaled A. Nasr and Keal Desai are Venture Members of IMP10. Each of the foregoing persons may be deemed to beneficially own the shares held by IW10, and each foregoing person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| September 29, 2020 Filed Oct 2, 2020 18:41 UTC Amendment | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | ConversionCommon Stock | 1,620,101 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-053342 · doc4a.xml · nonDerivative · entry 2 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Desai Keval · CIK 0001553019 · 10% owner Kliman Gilbert H · CIK 0001293171 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,675,656 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1 · ownership.direct: The securities are directly held by InterWest Partners X, LP ("IW10"). InterWest Management Partners X, LLC ("IMP10"), as the general partner of IW10, may be deemed to beneficially own the shares held by IW10. Arnold L. Oronsky and Gilbert H. Kliman are Managing Directors of IMP10, and Khaled A. Nasr and Keal Desai are Venture Members of IMP10. Each of the foregoing persons may be deemed to beneficially own the shares held by IW10, and each foregoing person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| September 25, 2020 Filed Sep 29, 2020 16:35 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | PurchaseCommonn Stock | 55,000 | $18.00 | $990,000.00 |
DisclosureSEC source: 0001209191-20-052335 · doc4.xml · nonDerivative · entry 1 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Desai Keval · CIK 0001553019 · 10% owner Kliman Gilbert H · CIK 0001293171 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 F1 · ownership.direct: The securities are directly held by InterWest Partners X, LP ("IW10"). InterWest Management Partners X, LLC ("IMP10"), as the general partner of IW10, may be deemed to beneficially own the shares held by IW10. Arnold L. Oronsky and Gilbert H. Kliman are Managing Directors of IMP10, and Khaled A. Nasr and Keal Desai are Venture Members of IMP10. Each of the foregoing persons may be deemed to beneficially own the shares held by IW10, and each foregoing person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| September 25, 2020 Filed Oct 2, 2020 18:41 UTC Amendment | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | PurchaseCommon Stock | 55,555 | $18.00 | $999,990.00 |
DisclosureSEC source: 0001209191-20-053342 · doc4a.xml · nonDerivative · entry 1 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Desai Keval · CIK 0001553019 · 10% owner Kliman Gilbert H · CIK 0001293171 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,555 F1 · ownership.direct: The securities are directly held by InterWest Partners X, LP ("IW10"). InterWest Management Partners X, LLC ("IMP10"), as the general partner of IW10, may be deemed to beneficially own the shares held by IW10. Arnold L. Oronsky and Gilbert H. Kliman are Managing Directors of IMP10, and Khaled A. Nasr and Keal Desai are Venture Members of IMP10. Each of the foregoing persons may be deemed to beneficially own the shares held by IW10, and each foregoing person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| November 21, 2019 Filed Nov 25, 2019 18:26 UTC | AVEDRO INC AVDR · Entity 153528 | OtherCommon Stock | 3,005 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-028099 · doc4.xml · nonDerivative · entry 2 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner ORONSKY ARNOLD L · CIK 0001207833 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Desai Keval · CIK 0001553019 · 10% owner Kliman Gilbert H · CIK 0001293171 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated as of August 7, 2019, by and among Avedro, Inc. (the "Issuer"), Glaukos Corporation ("Parent") and Atlantic Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), on November 21, 2019, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer continuing as the surviving corporation. Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of common stock of the Issuer ("Issuer Common Stock") that was issued and outstanding immediately prior to the Effective Time was automatically cancelled and converted into the right to receive 0.365 of a share of Parent's common stock ("Parent Common Stock"). The closing price of shares of the Parent Common Stock on November 21, 2019 was $63.07 per share. F3 · ownership.nature: The securities are directly held by InterWest Venture Management Company ("IVMC"). Gilbert H. Kliman transferred these shares to IVMC for no consideration pursuant to a contractual agreement between Kliman and IW10. Arnold L. Oronsky and Gilbert H. Kliman are owners, directors and officers of IVMC and as such may be deemed to beneficially own the shares held by IVMC. Each of Arnold L. Oronsky and Gilbert H. Kliman disclaim beneficial ownership of such shares except to the extend of his pecuniary interest therein. Read SEC document |
| November 21, 2019 Filed Nov 25, 2019 18:26 UTC | AVEDRO INC AVDR · Entity 153528 | OtherCommon Stock | 2,742,239 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-028099 · doc4.xml · nonDerivative · entry 1 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner ORONSKY ARNOLD L · CIK 0001207833 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Desai Keval · CIK 0001553019 · 10% owner Kliman Gilbert H · CIK 0001293171 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated as of August 7, 2019, by and among Avedro, Inc. (the "Issuer"), Glaukos Corporation ("Parent") and Atlantic Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), on November 21, 2019, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer continuing as the surviving corporation. Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of common stock of the Issuer ("Issuer Common Stock") that was issued and outstanding immediately prior to the Effective Time was automatically cancelled and converted into the right to receive 0.365 of a share of Parent's common stock ("Parent Common Stock"). The closing price of shares of the Parent Common Stock on November 21, 2019 was $63.07 per share. F2 · ownership.direct: The securities are directly held by InterWest Partners X, LP ("IW10"). InterWest Management Partners X, LLC ("IMP10"), as the general partner of IW10, may be deemed to beneficially own the shares held by IW10. Arnold L. Oronsky and Gilbert H. Kliman are Managing Directors of IMP10, and Khaled A. Nasr and Keal Desai are Venture Members of IMP10. Each of the foregoing persons may be deemed to beneficially own the shares held by IW10, and each foregoing person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| August 06, 2019 Filed Aug 8, 2019 11:10 UTC | Vyome Holdings, Inc OBLN · Entity 1824 | PurchaseWarrants (Right to buy) · Derivative | 18,750 | $0.00 Strike: $4.40 | $0.00 |
DisclosureSEC source: 0000899243-19-021334 · doc4.xml · derivative · entry 2 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner Kliman Gilbert H · CIK 0001293171 · 10% owner ORONSKY ARNOLD L · CIK 0001207833 · 10% owner Desai Keval · CIK 0001553019 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: COMMON · 18,750 shares Expires 2024-08-05 F1 · shares: The reporting persons purchased these shares directly from the underwriter in the Issuer's registered offering of Common Stock with 75% warrant coverage at a price of $4.00 per unit. There was no additional consideration paid for the warrants. F1 · price: The reporting persons purchased these shares directly from the underwriter in the Issuer's registered offering of Common Stock with 75% warrant coverage at a price of $4.00 per unit. There was no additional consideration paid for the warrants. F2 · balance_after: These securities are held of record by InterWest Partners X, L.P. ("IW10"). InterWest Management Partners X, LLC ("IMP10") is the general partner of IW10 and has sole voting and investment control over the shares owned by IW10. Gilbert H. Kliman, and Arnold L. Oronsky are Managing Directors of IMP10 and, Keval Desai and Khaled A. Nasr, and are Venture Members of IMP10. Douglas Fisher, a Member of IMP10 is also a Director of the Issuer, and when required, files a separate Form 4 in his own name. All Reporting Persons disclaim beneficial ownership of shares of Obalon Therapeutics, Inc. stock held by IW10, except to the extent of their respective pecuniary interest therein. The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1944, or otherwise, any of the Reporting Persons are the beneficial owner of all of the equity securities covered by this statement. Read SEC document |
| August 06, 2019 Filed Aug 8, 2019 11:10 UTC | Vyome Holdings, Inc OBLN · Entity 1824 | PurchaseCommon Stock | 25,000 | $4.00 | $100,000.00 |
DisclosureSEC source: 0000899243-19-021334 · doc4.xml · nonDerivative · entry 1 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner Kliman Gilbert H · CIK 0001293171 · 10% owner ORONSKY ARNOLD L · CIK 0001207833 · 10% owner Desai Keval · CIK 0001553019 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 380,224 F1 · shares: The reporting persons purchased these shares directly from the underwriter in the Issuer's registered offering of Common Stock with 75% warrant coverage at a price of $4.00 per unit. There was no additional consideration paid for the warrants. F1 · price: The reporting persons purchased these shares directly from the underwriter in the Issuer's registered offering of Common Stock with 75% warrant coverage at a price of $4.00 per unit. There was no additional consideration paid for the warrants. F2 · balance_after: These securities are held of record by InterWest Partners X, L.P. ("IW10"). InterWest Management Partners X, LLC ("IMP10") is the general partner of IW10 and has sole voting and investment control over the shares owned by IW10. Gilbert H. Kliman, and Arnold L. Oronsky are Managing Directors of IMP10 and, Keval Desai and Khaled A. Nasr, and are Venture Members of IMP10. Douglas Fisher, a Member of IMP10 is also a Director of the Issuer, and when required, files a separate Form 4 in his own name. All Reporting Persons disclaim beneficial ownership of shares of Obalon Therapeutics, Inc. stock held by IW10, except to the extent of their respective pecuniary interest therein. The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1944, or otherwise, any of the Reporting Persons are the beneficial owner of all of the equity securities covered by this statement. Read SEC document |
| February 19, 2019 Filed Feb 19, 2019 19:10 UTC | AVEDRO INC AVDR · Entity 153528 | ConversionSeries CC Convertible Preferred Stock · Derivative | 171,318 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-011329 · doc4.xml · derivative · entry 6 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner ORONSKY ARNOLD L · CIK 0001207833 · 10% owner Desai Keval · CIK 0001553019 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 171,318 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series AA Convertible Preferred Stock, Series BB Convertible Preferred Stock and Series CC Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of Series AA Convertible Preferred Stock, Series BB Convertible Preferred Stock and Series CC Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of Series AA Convertible Preferred Stock, Series BB Convertible Preferred Stock and Series CC Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F2 · ownership.direct: The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X") as the general partner of InterWest X may be deemed to beneficially own the shares held by InterWest X. Gilbert H. Kliman and Arnold L. Oronsky are Managing Directors of IMP X, and Keval Desai and Khaled A. Nasr are venture members of IMP X. Messrs. Kliman, Oronsky, Desai and Nasr may be deemed to beneficially own the shares held by InterWest X. Each of the foregoing persons disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| February 19, 2019 Filed Feb 19, 2019 19:10 UTC | AVEDRO INC AVDR · Entity 153528 | ConversionSeries BB Convertible Preferred Stock · Derivative | 222,119 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-011329 · doc4.xml · derivative · entry 5 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner ORONSKY ARNOLD L · CIK 0001207833 · 10% owner Desai Keval · CIK 0001553019 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 222,119 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series AA Convertible Preferred Stock, Series BB Convertible Preferred Stock and Series CC Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of Series AA Convertible Preferred Stock, Series BB Convertible Preferred Stock and Series CC Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of Series AA Convertible Preferred Stock, Series BB Convertible Preferred Stock and Series CC Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F2 · ownership.direct: The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X") as the general partner of InterWest X may be deemed to beneficially own the shares held by InterWest X. Gilbert H. Kliman and Arnold L. Oronsky are Managing Directors of IMP X, and Keval Desai and Khaled A. Nasr are venture members of IMP X. Messrs. Kliman, Oronsky, Desai and Nasr may be deemed to beneficially own the shares held by InterWest X. Each of the foregoing persons disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| February 19, 2019 Filed Feb 19, 2019 19:10 UTC | AVEDRO INC AVDR · Entity 153528 | ConversionSeries AA Convertible Preferred Stock · Derivative | 2,247,190 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-011329 · doc4.xml · derivative · entry 4 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner ORONSKY ARNOLD L · CIK 0001207833 · 10% owner Desai Keval · CIK 0001553019 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,247,190 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series AA Convertible Preferred Stock, Series BB Convertible Preferred Stock and Series CC Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of Series AA Convertible Preferred Stock, Series BB Convertible Preferred Stock and Series CC Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of Series AA Convertible Preferred Stock, Series BB Convertible Preferred Stock and Series CC Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F2 · ownership.direct: The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X") as the general partner of InterWest X may be deemed to beneficially own the shares held by InterWest X. Gilbert H. Kliman and Arnold L. Oronsky are Managing Directors of IMP X, and Keval Desai and Khaled A. Nasr are venture members of IMP X. Messrs. Kliman, Oronsky, Desai and Nasr may be deemed to beneficially own the shares held by InterWest X. Each of the foregoing persons disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| February 19, 2019 Filed Feb 19, 2019 19:10 UTC | AVEDRO INC AVDR · Entity 153528 | ConversionCommon Stock | 171,318 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-011329 · doc4.xml · nonDerivative · entry 3 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner ORONSKY ARNOLD L · CIK 0001207833 · 10% owner Desai Keval · CIK 0001553019 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,742,239 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series AA Convertible Preferred Stock, Series BB Convertible Preferred Stock and Series CC Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F2 · ownership.direct: The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X") as the general partner of InterWest X may be deemed to beneficially own the shares held by InterWest X. Gilbert H. Kliman and Arnold L. Oronsky are Managing Directors of IMP X, and Keval Desai and Khaled A. Nasr are venture members of IMP X. Messrs. Kliman, Oronsky, Desai and Nasr may be deemed to beneficially own the shares held by InterWest X. Each of the foregoing persons disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| February 19, 2019 Filed Feb 19, 2019 19:10 UTC | AVEDRO INC AVDR · Entity 153528 | ConversionCommon Stock | 222,119 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-011329 · doc4.xml · nonDerivative · entry 2 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner ORONSKY ARNOLD L · CIK 0001207833 · 10% owner Desai Keval · CIK 0001553019 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,570,921 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series AA Convertible Preferred Stock, Series BB Convertible Preferred Stock and Series CC Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F2 · ownership.direct: The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X") as the general partner of InterWest X may be deemed to beneficially own the shares held by InterWest X. Gilbert H. Kliman and Arnold L. Oronsky are Managing Directors of IMP X, and Keval Desai and Khaled A. Nasr are venture members of IMP X. Messrs. Kliman, Oronsky, Desai and Nasr may be deemed to beneficially own the shares held by InterWest X. Each of the foregoing persons disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| February 19, 2019 Filed Feb 19, 2019 19:10 UTC | AVEDRO INC AVDR · Entity 153528 | ConversionCommon Stock | 2,247,190 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-011329 · doc4.xml · nonDerivative · entry 1 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner ORONSKY ARNOLD L · CIK 0001207833 · 10% owner Desai Keval · CIK 0001553019 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,348,802 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series AA Convertible Preferred Stock, Series BB Convertible Preferred Stock and Series CC Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F2 · ownership.direct: The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X") as the general partner of InterWest X may be deemed to beneficially own the shares held by InterWest X. Gilbert H. Kliman and Arnold L. Oronsky are Managing Directors of IMP X, and Keval Desai and Khaled A. Nasr are venture members of IMP X. Messrs. Kliman, Oronsky, Desai and Nasr may be deemed to beneficially own the shares held by InterWest X. Each of the foregoing persons disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| October 18, 2018 Filed Oct 22, 2018 16:33 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | SaleCommon Stock | 26,465 | $12.00 | $317,606.47 |
DisclosureSEC source: 0000899243-18-027169 · doc4.xml · nonDerivative · entry 2 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner Kliman Gilbert H · CIK 0001293171 · 10% owner ORONSKY ARNOLD L · CIK 0001207833 · 10% owner Desai Keval · CIK 0001553019 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,362,327 F2 · price: Price reflected is the weighted-average sale price for shares sold. The range of sale prices for the transactions reported was $12.00 to $12.03 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: These securities are held of record by InterWest Partners X, L.P. ("IW10"). InterWest Management Partners X, LLC ("IMP10") is the general partner of IW10 and has sole voting and investment control over the shares owned by IW10. Gilbert H. Kliman, and Arnold L. Oronsky are Managing Directors of IMP10 and, Keval Desai and Khaled A. Nasr, are Venture Members of IMP10. All Reporting Persons disclaim beneficial ownership of shares of Eiger BioPharmaceuticals, Inc. stock held by IW10, except to the extent of their respective pecuniary interest therein. The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1944, or otherwise, any of the Reporting Persons are the beneficial owner of all of the equity securities covered by this statement. Read SEC document |
| October 18, 2018 Filed Oct 22, 2018 16:33 UTC | Eiger BioPharmaceuticals, Inc. EIGR · Entity 16554 | SaleCommon Stock | 210,800 | $12.07 | $2,544,714.36 |
DisclosureSEC source: 0000899243-18-027169 · doc4.xml · nonDerivative · entry 1 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner Kliman Gilbert H · CIK 0001293171 · 10% owner ORONSKY ARNOLD L · CIK 0001207833 · 10% owner Desai Keval · CIK 0001553019 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,388,792 F1 · price: Price reflected is the weighted-average sale price for shares sold. The range of sale prices for the transactions reported was $12.00 to $12.30 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: These securities are held of record by InterWest Partners X, L.P. ("IW10"). InterWest Management Partners X, LLC ("IMP10") is the general partner of IW10 and has sole voting and investment control over the shares owned by IW10. Gilbert H. Kliman, and Arnold L. Oronsky are Managing Directors of IMP10 and, Keval Desai and Khaled A. Nasr, are Venture Members of IMP10. All Reporting Persons disclaim beneficial ownership of shares of Eiger BioPharmaceuticals, Inc. stock held by IW10, except to the extent of their respective pecuniary interest therein. The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1944, or otherwise, any of the Reporting Persons are the beneficial owner of all of the equity securities covered by this statement. Read SEC document |
| August 23, 2018 Filed Aug 27, 2018 16:24 UTC | Vyome Holdings, Inc OBLN · Entity 1824 | PurchaseCommon Stock | 1,098,901 | $1.82 | $1,999,999.82 |
DisclosureSEC source: 0000899243-18-023312 · doc4.xml · nonDerivative · entry 1 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner Kliman Gilbert H · CIK 0001293171 · 10% owner ORONSKY ARNOLD L · CIK 0001207833 · 10% owner Desai Keval · CIK 0001553019 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,552,239 F1 · shares: The reporting person purchased these shares directly from the issuer in a private placement. F2 · balance_after: These securities are held of record by InterWest Partners X, L.P. ("IW10"). InterWest Management Partners X, LLC ("IMP10") is the general partner of IW10 and has sole voting and investment control over the shares owned by IW10. Gilbert H. Kliman, and Arnold L. Oronsky are Managing Directors of IMP10 and, Keval Desai and Khaled A. Nasr, and are Venture Members of IMP10. Douglas Fisher, a Member of IMP10 is also a Director of the Issuer, and when required, files a separate Form 4 in his own name. All Reporting Persons disclaim beneficial ownership of shares of Obalon Therapeutics, Inc. stock held by IW10, except to the extent of their respective pecuniary interest therein. The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1944, or otherwise, any of the Reporting Persons are the beneficial owner of all of the equity securities covered by this statement. Read SEC document |
| October 12, 2016 Filed Oct 12, 2016 17:34 UTC | Vyome Holdings, Inc OBLN · Entity 1824 | ConversionSeries E Preferred Stock · Derivative | 373,803 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-16-145722 · doc4.xml · derivative · entry 6 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner GIANOS PHILIP T · CIK 0001207831 · 10% owner Holmes W Stephen · CIK 0001293923 · 10% owner Kliman Gilbert H · CIK 0001293171 · 10% owner ORONSKY ARNOLD L · CIK 0001207833 · 10% owner Desai Keval · CIK 0001553019 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 373,803 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of the issuer's Series E Preferred Stock automatically converted into 1 share of the issuer's Common Stock on October 12, 2016 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F4 · price: Each share of the issuer's Series E Preferred Stock automatically converted into 1 share of the issuer's Common Stock on October 12, 2016 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F4 · derivative.exercise_date: Each share of the issuer's Series E Preferred Stock automatically converted into 1 share of the issuer's Common Stock on October 12, 2016 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F4 · derivative.expiration_date: Each share of the issuer's Series E Preferred Stock automatically converted into 1 share of the issuer's Common Stock on October 12, 2016 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.direct: These securities are held of record by InterWest Partners X, L.P. ("IW10"). InterWest Management Partners X, LLC ("IMP10") is the general partner of IW10. Philip T. Gianos, W. Stephen Holmes, Gilbert H. Kliman and Arnold L. Oronsky are the managing directors of IMP10, and Keval Desai and Khalad A. Nasr are venture members of IMP10. Each of the reporting persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. The reporting persons have designated a representative, currently Doug Fisher, a consultant of InterWest Venture Management Co., to serve on the issuer's board of directors. This report shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes. Read SEC document |
| October 12, 2016 Filed Oct 12, 2016 17:34 UTC | Vyome Holdings, Inc OBLN · Entity 1824 | ConversionSeries D Preferred Stock · Derivative | 464,494 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-16-145722 · doc4.xml · derivative · entry 5 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner GIANOS PHILIP T · CIK 0001207831 · 10% owner Holmes W Stephen · CIK 0001293923 · 10% owner Kliman Gilbert H · CIK 0001293171 · 10% owner ORONSKY ARNOLD L · CIK 0001207833 · 10% owner Desai Keval · CIK 0001553019 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 464,494 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of the issuer's Series D Preferred Stock automatically converted into 1 share of the issuer's Common Stock on October 12, 2016 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F3 · price: Each share of the issuer's Series D Preferred Stock automatically converted into 1 share of the issuer's Common Stock on October 12, 2016 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F3 · derivative.exercise_date: Each share of the issuer's Series D Preferred Stock automatically converted into 1 share of the issuer's Common Stock on October 12, 2016 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F3 · derivative.expiration_date: Each share of the issuer's Series D Preferred Stock automatically converted into 1 share of the issuer's Common Stock on October 12, 2016 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.direct: These securities are held of record by InterWest Partners X, L.P. ("IW10"). InterWest Management Partners X, LLC ("IMP10") is the general partner of IW10. Philip T. Gianos, W. Stephen Holmes, Gilbert H. Kliman and Arnold L. Oronsky are the managing directors of IMP10, and Keval Desai and Khalad A. Nasr are venture members of IMP10. Each of the reporting persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. The reporting persons have designated a representative, currently Doug Fisher, a consultant of InterWest Venture Management Co., to serve on the issuer's board of directors. This report shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes. Read SEC document |
| October 12, 2016 Filed Oct 12, 2016 17:34 UTC | Vyome Holdings, Inc OBLN · Entity 1824 | ConversionSeries C Preferred Stock · Derivative | 1,615,041 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-16-145722 · doc4.xml · derivative · entry 4 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner GIANOS PHILIP T · CIK 0001207831 · 10% owner Holmes W Stephen · CIK 0001293923 · 10% owner Kliman Gilbert H · CIK 0001293171 · 10% owner ORONSKY ARNOLD L · CIK 0001207833 · 10% owner Desai Keval · CIK 0001553019 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,615,041 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the issuer's Series C Preferred Stock automatically converted into 1 share of the issuer's Common Stock on October 12, 2016 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-213551) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F1 · price: Each share of the issuer's Series C Preferred Stock automatically converted into 1 share of the issuer's Common Stock on October 12, 2016 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-213551) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F1 · derivative.exercise_date: Each share of the issuer's Series C Preferred Stock automatically converted into 1 share of the issuer's Common Stock on October 12, 2016 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-213551) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F1 · derivative.expiration_date: Each share of the issuer's Series C Preferred Stock automatically converted into 1 share of the issuer's Common Stock on October 12, 2016 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-213551) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F2 · ownership.direct: These securities are held of record by InterWest Partners X, L.P. ("IW10"). InterWest Management Partners X, LLC ("IMP10") is the general partner of IW10. Philip T. Gianos, W. Stephen Holmes, Gilbert H. Kliman and Arnold L. Oronsky are the managing directors of IMP10, and Keval Desai and Khalad A. Nasr are venture members of IMP10. Each of the reporting persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. The reporting persons have designated a representative, currently Doug Fisher, a consultant of InterWest Venture Management Co., to serve on the issuer's board of directors. This report shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes. Read SEC document |
| October 12, 2016 Filed Oct 12, 2016 17:34 UTC | Vyome Holdings, Inc OBLN · Entity 1824 | ConversionCommon Stock | 373,803 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-16-145722 · doc4.xml · nonDerivative · entry 3 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner GIANOS PHILIP T · CIK 0001207831 · 10% owner Holmes W Stephen · CIK 0001293923 · 10% owner Kliman Gilbert H · CIK 0001293171 · 10% owner ORONSKY ARNOLD L · CIK 0001207833 · 10% owner Desai Keval · CIK 0001553019 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,453,338 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each share of the issuer's Series E Preferred Stock automatically converted into 1 share of the issuer's Common Stock on October 12, 2016 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.direct: These securities are held of record by InterWest Partners X, L.P. ("IW10"). InterWest Management Partners X, LLC ("IMP10") is the general partner of IW10. Philip T. Gianos, W. Stephen Holmes, Gilbert H. Kliman and Arnold L. Oronsky are the managing directors of IMP10, and Keval Desai and Khalad A. Nasr are venture members of IMP10. Each of the reporting persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. The reporting persons have designated a representative, currently Doug Fisher, a consultant of InterWest Venture Management Co., to serve on the issuer's board of directors. This report shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes. Read SEC document |
| October 12, 2016 Filed Oct 12, 2016 17:34 UTC | Vyome Holdings, Inc OBLN · Entity 1824 | ConversionCommon Stock | 464,494 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-16-145722 · doc4.xml · nonDerivative · entry 2 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner GIANOS PHILIP T · CIK 0001207831 · 10% owner Holmes W Stephen · CIK 0001293923 · 10% owner Kliman Gilbert H · CIK 0001293171 · 10% owner ORONSKY ARNOLD L · CIK 0001207833 · 10% owner Desai Keval · CIK 0001553019 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,079,535 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each share of the issuer's Series D Preferred Stock automatically converted into 1 share of the issuer's Common Stock on October 12, 2016 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.direct: These securities are held of record by InterWest Partners X, L.P. ("IW10"). InterWest Management Partners X, LLC ("IMP10") is the general partner of IW10. Philip T. Gianos, W. Stephen Holmes, Gilbert H. Kliman and Arnold L. Oronsky are the managing directors of IMP10, and Keval Desai and Khalad A. Nasr are venture members of IMP10. Each of the reporting persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. The reporting persons have designated a representative, currently Doug Fisher, a consultant of InterWest Venture Management Co., to serve on the issuer's board of directors. This report shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes. Read SEC document |
| October 12, 2016 Filed Oct 12, 2016 17:34 UTC | Vyome Holdings, Inc OBLN · Entity 1824 | ConversionCommon Stock | 1,615,041 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-16-145722 · doc4.xml · nonDerivative · entry 1 INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner GIANOS PHILIP T · CIK 0001207831 · 10% owner Holmes W Stephen · CIK 0001293923 · 10% owner Kliman Gilbert H · CIK 0001293171 · 10% owner ORONSKY ARNOLD L · CIK 0001207833 · 10% owner Desai Keval · CIK 0001553019 · 10% owner NASR KHALED · CIK 0001276600 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,615,041 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the issuer's Series C Preferred Stock automatically converted into 1 share of the issuer's Common Stock on October 12, 2016 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-213551) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F2 · ownership.direct: These securities are held of record by InterWest Partners X, L.P. ("IW10"). InterWest Management Partners X, LLC ("IMP10") is the general partner of IW10. Philip T. Gianos, W. Stephen Holmes, Gilbert H. Kliman and Arnold L. Oronsky are the managing directors of IMP10, and Keval Desai and Khalad A. Nasr are venture members of IMP10. Each of the reporting persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. The reporting persons have designated a representative, currently Doug Fisher, a consultant of InterWest Venture Management Co., to serve on the issuer's board of directors. This report shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.